BioWorld
-
‘Fergene’ therapy in BCG-stubborn bladder cancer, Instiladrin instills phase III confidence
-
Emphasizing synergy and efficiency, EOC Pharma raises $71M series C to fight breast, gastric cancers
-
New PCa treatment strategy may overcome resistance
-
Dyno to scale the heights of AAV vector engineering
-
With another $26M, Japan’s Heartseed aims to advance iPSC-derived regenerative medicine for heart failure
-
Ipsen falls on FDA hold for bone disorder drug palovarotene
-
Bench Press for Dec. 6, 2019
-
Biopharma equities push higher once again in November
-
Key for aducanumab success: higher dose, longer exposure
BioWorld MedTech
-
Viewray sees an additional $139M with collaborations with Elekta, Medtronic
-
Israeli, U.S. teams collaborate on technology for respiratory tract diseases
-
FDA grants rare pediatric disease status for outer ear reconstruction system
-
U.S. health spending rises to $3.6T in 2018, but falls as share of GDP
-
TGA goes back to the drawing board again with guidance on custom-made and 3D-printed devices
-
Bioworld MedTech’s Neurology Extra for Dec. 6, 2019
-
FDA gives 510(k) nod to Moleculight’s wound assessment device
-
Akoya Biosciences rakes in $50M to back CODEX, Phenoptics platforms
-
Micro-leads raises $10M to develop and test precision spinal cord stimulation
BioWorld Asia
-
Celltrion’s Remsima SC wins marketing approval in EU
-
China updates reimbursement drug list, further encourages innovation at home
-
GI Innovation licenses GI-101 to Simcere at maximum $796 million
-
Australia’s Opthea raises AU$50M to advance OPT-302 to phase III in wet AMD
-
Indian pharma sector needs to learn from its competitors: report
-
In India, government steps up efforts to develop more TB testing and treatment
